Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?

Key Takeaways Ironwood expects 2026 revenues of $450-$475M, up 54% Y/Y at midpoint, on high Linzess demand.Ironwood is advancing apraglutide toward a phase III study in 1H26 following an FDA meeting.BHC guided 2026 revenues of $10.625-$10.875B, with $5.375-$5.475B from Bausch plus Lomb.Ironwood Pharmaceuticals (IRWD) and Bausch Health (BHC) operate in the branded gastrointestinal (GI) drug market, with a focus on treatments for irritable bowel syndrome (IBS) and other therapeutic areas.While Ironwood is a s ...